Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Adv Halt Trial

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Chimerix
ClinicalTrials.gov Identifier:
NCT01241344
First received: November 12, 2010
Last updated: October 31, 2013
Last verified: October 2013

November 12, 2010
October 31, 2013
November 2010
June 2013   (final data collection date for primary outcome measure)
The primary objective of this study is to evaluate the safety and efficacy of preemptive treatment with CMX001 versus placebo for the prevention of AdV disease in recipients of HSCT with asymptomatic AdV viremia [ Designated as safety issue: Yes ]

The outcome measure for the primary endpoint will be "treatment failure". Treatment failure is a composite endpoint consisting of:

  • Progression to probable or definitive AdV disease.
  • OR increasing AdV viremia during randomized therapy (defined as increase from baseline in AdV viremia by ≥ 1 log10, confirmed on a second measurement, at least one week apart) AND requiring discontinuation from randomized therapy
Same as current
Complete list of historical versions of study NCT01241344 on ClinicalTrials.gov Archive Site
1. To compare the safety and efficacy of two dosing regimens of CMX001 versus each other and versus placebo in this indication. [ Designated as safety issue: Yes ]

2. To compare the incidence of treatment emergent dsDNA viral infections (other than those caused by AdV), in subjects treated with CMX001 QW versus CMX001 BIW versus placebo, initially, for the preemption of adenoviral disease.

3. To characterize the safety and efficacy of CMX001 open-label therapy in patients who meet the primary endpoint of treatment failure during randomized therapy.

Same as current
Not Provided
Not Provided
 
The Adv Halt Trial
A Randomized, Placebo-Controlled Multi-Site Phase 2 Study Evaluation the Safety and Efficacy of Preemptive Treatment With CMX001 for the Prevention of Adenovirus Disease Following Hematopoietic Stem Cell Transplantation in Adults and Children

The primary objective of this study is to evaluate the safety and efficacy of preemptive treatment with CMX001 versus placebo for the prevention of AdV disease in recipients of HSCT with asymptomatic AdV viremia.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Adenovirus Disease
Drug: CMX001
  • Adults: 200mg CMX001 given as four 50mg tablets orally either QW OR BIW.
  • Peds: 4mg/kg (NTE a total single dose of 200mg) given using a 5 mg/mL liquid formulation taken orally either QW OR BIW
  • Active Comparator: CMX001
    • Adults: 200mg CMX001 given as four 50mg tablets orally either QW OR BIW.
    • Peds: 4mg/kg (NTE a total single dose of 200mg) given using a 5 mg/mL liquid formulation taken orally either QW OR BIW
    Intervention: Drug: CMX001
  • Placebo Comparator: Placebo
    • Adults: Two matching placebo tablets taken orally QW OR BIW.
    • Peds: Matching liquid placebo taken orally QW OR BIW
    Intervention: Drug: CMX001
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
52
June 2013
June 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Males and females ≥ 3 months and ≤ 75 years of age.
  2. Subjects have received an allogeneic HSCT.
  3. Positive serum AdV PCR (> 100 copies/mL) as measured by the central laboratory.
  4. Subject or guardian(s) are willing to comply with the protocol.
  5. Subject or guardian(s) are willing and able to understand the informed consent/assent.
  6. Females of child-bearing potential must have a negative pregnancy test (serum beta-hCG) and sexually active females must use a reliable and medically approved method of contraception throughout the study. Sexually active males of procreation potential must be able and willing to use a reliable and medically approved contraceptive method throughout the study. At least one barrier method of contraception must be used, in subjects of procreation potential.

Exclusion Criteria:

  1. Subject has possible, probable, or definitive AdV disease. See Appendix 2Error! Reference source not found. for a definition and criteria outlining possible, probable or definitive AdV disease.
  2. Suspected gut graft versus host disease (GVHD) that is not biopsy-proven (subjects with a biopsy performed may be included in the study).
  3. Subject has an eGFR ≤ 30 mL/minute and is not currently on dialysis.
  4. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 10 times the ULN, conjugated bilirubin > 5 times the upper limit of normal (ULN).
  5. Subject has mucositis preventing ingestion of oral medication.
  6. Subject is Human Immunodeficiency Virus (HIV) antibody positive, based upon available medical records.
  7. Subject has ocular hypotony, uveitis, or retinitis or any other intraocular pathology that would predispose the subject to one of these conditions.
  8. Subject has participated in any other investigational drug study or was exposed to an investigational drug within 14 days of enrollment.
  9. Is pregnant or breast-feeding or intending to conceive during the course of the study, including the follow-up period after drug discontinuation.
  10. Known immunologic hypersensitivity to CDV or CMX001 drug or any of its excipients.
  11. History of illicit drug use or alcohol abuse within the previous 6 months.
  12. Any medical condition that, in the opinion of the Investigator, might interfere with the subject's participation in the study, poses an added risk for the subject, or confounds the assessment of the subject (e.g. severe cardiovascular, central nervous system (CNS) or pulmonary disease).
  13. Subject has received CMX001, CDV, ribavirin, or leflunomide within the previous 14 days.
Both
3 Months to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01241344
CMX001-202
Not Provided
Chimerix
Chimerix
Not Provided
Not Provided
Chimerix
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP